JP2022521973A - 抗ｃｄ６抗体組成物およびループスを処置するための方法 - Google Patents

抗ｃｄ６抗体組成物およびループスを処置するための方法 Download PDF

Info

Publication number
JP2022521973A
JP2022521973A JP2021549772A JP2021549772A JP2022521973A JP 2022521973 A JP2022521973 A JP 2022521973A JP 2021549772 A JP2021549772 A JP 2021549772A JP 2021549772 A JP2021549772 A JP 2021549772A JP 2022521973 A JP2022521973 A JP 2022521973A
Authority
JP
Japan
Prior art keywords
alcam
subject
soluble
sample
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021549772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521973A5 (enExample
Inventor
コネリー，スティーヴン
ポル，クリシュナ
モハン，チャンドラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Equillium Inc
Original Assignee
Equillium Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equillium Inc filed Critical Equillium Inc
Publication of JP2022521973A publication Critical patent/JP2022521973A/ja
Publication of JP2022521973A5 publication Critical patent/JP2022521973A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2021549772A 2019-02-26 2020-02-26 抗ｃｄ６抗体組成物およびループスを処置するための方法 Ceased JP2022521973A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962810628P 2019-02-26 2019-02-26
US62/810,628 2019-02-26
US201962933294P 2019-11-08 2019-11-08
US62/933,294 2019-11-08
PCT/US2020/019990 WO2020176682A1 (en) 2019-02-26 2020-02-26 Anti-cd6 antibody compositions and methods for treating lupus

Publications (2)

Publication Number Publication Date
JP2022521973A true JP2022521973A (ja) 2022-04-13
JP2022521973A5 JP2022521973A5 (enExample) 2023-03-02

Family

ID=70009403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549772A Ceased JP2022521973A (ja) 2019-02-26 2020-02-26 抗ｃｄ６抗体組成物およびループスを処置するための方法

Country Status (12)

Country Link
US (1) US20220143140A1 (enExample)
EP (1) EP3930751A1 (enExample)
JP (1) JP2022521973A (enExample)
CN (1) CN113490511B (enExample)
AU (1) AU2020229830A1 (enExample)
BR (1) BR112021016967A2 (enExample)
CA (1) CA3131299A1 (enExample)
MX (1) MX2021010283A (enExample)
PH (1) PH12021551994A1 (enExample)
SG (1) SG11202109118XA (enExample)
WO (1) WO2020176682A1 (enExample)
ZA (1) ZA202107077B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
JP2023552762A (ja) * 2020-12-04 2023-12-19 エクイリウム，インコーポレイテッド Ｃｄ６ｈｉｇｈ細胞を選択的に標的化してｔｅｆｆ細胞の活性を低下する方法
EP4533094A4 (en) * 2022-05-25 2026-05-06 Univ Houston System Methods and systems for risk stratification and management of bladder cancer
TWI869873B (zh) * 2023-06-05 2025-01-11 中國醫藥大學 一種檢測一個體罹患單純復發性風濕病的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000500661A (ja) * 1996-07-18 2000-01-25 デューク ユニヴァーシティー Ｃｄ６リガンド
JP2001523956A (ja) * 1997-03-03 2001-11-27 ブリストル−マイヤーズ・スクイブ・カンパニー ヒトｃｄ６に対するモノクローナル抗体
JP2011513479A (ja) * 2008-03-14 2011-04-28 バイオコン・リミテッド モノクローナル抗体、及びその（ｔｈｅｒｏｆ）方法
WO2012133047A1 (ja) * 2011-03-25 2012-10-04 コニカミノルタエムジー株式会社 免疫組織染色法、およびこれを用いた抗体医薬の有効性を判定する方法
WO2018073734A1 (en) * 2016-10-21 2018-04-26 Biocon Limited A monoclonal antibody and a method of use for the treatment of lupus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
KR101482959B1 (ko) 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
BR112013033988B1 (pt) * 2011-07-01 2021-10-19 Beckman Coulter, Inc. Métodos de identificação e isolamento de uma ou mais populações de células t regulatórias imunossupressoras
AU2013229786B2 (en) * 2012-03-08 2017-06-22 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2015107501A1 (en) * 2014-01-20 2015-07-23 Ghiggeri Gian Marco In vitro method for predicting, diagnosing and monitoring in therapeutic follow up lupus nephritis
EP3439658B1 (en) * 2016-04-04 2021-11-24 ChemoCentryx, Inc. Soluble c5ar antagonists
WO2017214452A1 (en) * 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000500661A (ja) * 1996-07-18 2000-01-25 デューク ユニヴァーシティー Ｃｄ６リガンド
JP2001523956A (ja) * 1997-03-03 2001-11-27 ブリストル−マイヤーズ・スクイブ・カンパニー ヒトｃｄ６に対するモノクローナル抗体
JP2011513479A (ja) * 2008-03-14 2011-04-28 バイオコン・リミテッド モノクローナル抗体、及びその（ｔｈｅｒｏｆ）方法
WO2012133047A1 (ja) * 2011-03-25 2012-10-04 コニカミノルタエムジー株式会社 免疫組織染色法、およびこれを用いた抗体医薬の有効性を判定する方法
WO2018073734A1 (en) * 2016-10-21 2018-04-26 Biocon Limited A monoclonal antibody and a method of use for the treatment of lupus

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CHRISTELLE LE DANTEC; ET AL: "RATIONALE FOR TREATING PRIMARY SJOGREN'S SYNDROME PATIENTS WITH AN ANTI-CD6 MONOCLONAL ANTIBODY (ITO", IMMUNOLOGIC RESEARCH, vol. VOL:56, NR:2-3, JPN5022006329, 11 April 2013 (2013-04-11), US, pages 341 - 347, ISSN: 0005214847 *
EVAN DER: "CD6-ALCAM Signaling Is Upregulated in Kidneys with Lupus Nephritis and Is Associated with Disease Ac", ARTHRITIS & RHEUMATOLOGY, vol. 71, no. 10, JPN6023050528, October 2019 (2019-10-01), pages 2894, ISSN: 0005532656 *
IOANNIS PARODIS: "A Role of Vascular Cell Adhesion Molecule 1 and Activated Leukocyte Cell Adhesion Molecule in LUPUS", ARTHRITIS & RHEUMATOLOGY, vol. 70, no. 9, JPN6023050523, September 2018 (2018-09-01), pages 2127, ISSN: 0005214849 *
LEE I GARNER: "CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action", IMMUNOLOGY, vol. 155, no. 2, JPN6023050529, 13 June 2018 (2018-06-13), pages 273 - 282, ISSN: 0005532658 *
M RAMOS-CASALS: "High circulating levels of soluble scavenger receptors (sCD5 and sCD6) in patients with primary Sjog", RHEUMATOLOGY, vol. 40, no. 9, JPN6023050522, September 2001 (2001-09-01), pages 1056 - 1059, ISSN: 0005214848 *
MARTA CONSUEGRA-FERNANDEZ; ET AL: "CLINICAL AND EXPERIMENTAL EVIDENCE FOR TARGETING CD6 IN IMMUNE-BASED DISORDERS", AUTOIMMUNITY REVIEWS, vol. VOL:17, NR:5, JPN5022006328, May 2018 (2018-05-01), NL, pages 493 - 503, ISSN: 0005532657 *
PATRICIA HERNANDEZ: "Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Ant", CURRENT DRUG TARGETS, vol. 17, JPN6023050527, 2016, pages 666 - 677, ISSN: 0005532655 *
SAMANTHA A. CHALMERS: "The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses", J CLIN INVEST, vol. 132, no. 1, JPN6023050526, 4 January 2022 (2022-01-04), pages 147334, ISSN: 0005532654 *
SAMANTHA STANLEY: "Comprehensive Aptamer-Based Screening of 1129Proteins Reveals Novel Urinary Biomarkers of LUPUS neph", ARTHRITIS & RHEUMATOLOGY, vol. 68, no. 10, JPN6023050524, October 2016 (2016-10-01), pages 2820, ISSN: 0005214850 *
稲田進一: "抗核抗体と自己免疫疾患", 臨床化学, vol. 第27巻, 第3号, JPN6021045962, 1998, pages 138 - 145, ISSN: 0005532659 *
米国EQUILLIUM社と抗CD6抗体「ITOLIZUMAB」の開発・商業化に関する独占的オプション権付アセット買収契約を, JPN6023050525, 6 December 2022 (2022-12-06), ISSN: 0005532653 *

Also Published As

Publication number Publication date
SG11202109118XA (en) 2021-09-29
CN113490511B (zh) 2024-07-09
PH12021551994A1 (en) 2022-08-15
ZA202107077B (en) 2023-07-26
CN113490511A (zh) 2021-10-08
CA3131299A1 (en) 2020-09-03
BR112021016967A2 (pt) 2021-11-23
MX2021010283A (es) 2021-09-30
EP3930751A1 (en) 2022-01-05
AU2020229830A1 (en) 2021-09-16
WO2020176682A1 (en) 2020-09-03
US20220143140A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
JP2022521973A (ja) 抗ｃｄ６抗体組成物およびループスを処置するための方法
US11725246B2 (en) Methods of treating ophthalmic disorders
EP3250599B1 (en) Biomarker
KR102223464B1 (ko) Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법
KR20150010709A (ko) Il-17 길항제를 사용하는 강직성 척추염의 치료 방법
MX2015003932A (es) Metodos para diagnosticar y tratar la enfermedad inflamatoria intestinal.
US20250334594A1 (en) Methods for the treatment of amyotrophic lateral sclerosis
US20230112035A1 (en) ANTI-avB8 INTEGRIN ANTIBODIES FOR USE IN TREATING KIDNEY DISEASE
WO2014155278A2 (en) Methods of treating autoimmune diseases using il-17 antagonists
HK40052994A (en) Anti-cd6 antibody compositions and methods for treating lupus
HK40052994B (zh) 用於治疗狼疮的抗cd6抗体组合物和方法
EP4229417A1 (en) Proteome analysis in pulmonary hypertension
IL291776A (en) Method of predicting requirement for biologic therapy
BR112020016400A2 (pt) Anticorpos para o ligante do receptor de tirosina cinase 3 similar ao sarcoma felino de mcdonough (fms) (flt3l) e suas utilizações para o tratamento de doenças autoimunes e inflamatórias
JP6964322B2 (ja) ループス腎炎を処置または予防するための医薬組成物およびループス腎炎のバイオマーカー
KR20250138273A (ko) 뇌척수액에서 바이오마커를 검출함으로써 다발성 경화증을 진단 및 치료하는 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240307

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240927

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241115

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250220

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20250620